

# Luis G Bermúdez-Humarán

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1209052/publications.pdf>

Version: 2024-02-01

143  
papers

13,782  
citations

31902

53  
h-index

22102

113  
g-index

156  
all docs

156  
docs citations

156  
times ranked

15300  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome Sequence and Assessment of Safety and Potential Probiotic Traits of <i>Lactobacillus johnsonii</i> CNCM I-4884. <i>Microorganisms</i> , 2022, 10, 273.	1.6	8
2	Looking inside Mexican Traditional Food as Sources of Synbiotics for Developing Novel Functional Products. <i>Fermentation</i> , 2022, 8, 123.	1.4	7
3	Functional characterization of $\hat{\pm}$ -Gal producing lactic acid bacteria with potential probiotic properties. <i>Scientific Reports</i> , 2022, 12, 7484.	1.6	8
4	Assessment of the Safety and Efficacy of an Oral Probiotic-Based Vaccine Against <i>Aspergillus</i> Infection in Captive-Bred Humboldt Penguins ( <i>Spheniscus humboldti</i> ). <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
5	Functional Foods, Nutraceuticals and Probiotics: A Focus on Human Health. <i>Microorganisms</i> , 2022, 10, 1065.	1.6	48
6	Effects of a Modern Kefir on Conditions Associated with Moderate Severe Spastic Quadriplegia Cerebral Palsy. <i>Microorganisms</i> , 2022, 10, 1291.	1.6	2
7	Strategies for the Identification and Assessment of Bacterial Strains with Specific Probiotic Traits. <i>Microorganisms</i> , 2022, 10, 1389.	1.6	6
8	Twenty years of research on HPV vaccines based on genetically modified lactic acid bacteria: an overview on the gut-vagina axis. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 1191-1206.	2.4	27
9	The Administration Matrix Modifies the Beneficial Properties of a Probiotic Mix of <i>Bifidobacterium animalis</i> subsp. <i>lactis</i> BB-12 and <i>Lactobacillus acidophilus</i> LA-5. <i>Probiotics and Antimicrobial Proteins</i> , 2021, 13, 484-494.	1.9	11
10	Modulation of the PI3K/Akt/mTOR signaling pathway by probiotics as a fruitful target for orchestrating the immune response. <i>Gut Microbes</i> , 2021, 13, 1-17.	4.3	48
11	Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease. <i>Vaccines</i> , 2021, 9, 466.	2.1	30
12	Antioxidant and Anti-Inflammatory Properties of Probiotic Candidate Strains Isolated during Fermentation of Agave ( <i>Agave angustifolia</i> Haw). <i>Microorganisms</i> , 2021, 9, 1063.	1.6	13
13	Role of Gut Microbiota and Probiotics in Colorectal Cancer: Onset and Progression. <i>Microorganisms</i> , 2021, 9, 1021.	1.6	34
14	Bioactive Compounds in Food as a Current Therapeutic Approach to Maintain a Healthy Intestinal Epithelium. <i>Microorganisms</i> , 2021, 9, 1634.	1.6	17
15	Age and <i>Giardia intestinalis</i> Infection Impact Canine Gut Microbiota. <i>Microorganisms</i> , 2021, 9, 1862.	1.6	10
16	Probiotics and Trained Immunity. <i>Biomolecules</i> , 2021, 11, 1402.	1.8	17
17	Probiotics against Viral Infections: Current Clinical Trials and Future Perspectives. <i>Immuno</i> , 2021, 1, 468-498.	0.6	3
18	Probiotic Properties of <i>Lactobacillus</i> Strains Isolated from Table Olive Biofilms. <i>Probiotics and Antimicrobial Proteins</i> , 2020, 12, 1071-1082.	1.9	16

#	ARTICLE	IF	CITATIONS
19	Butyrate mediates anti-inflammatory effects of <i>Faecalibacterium prausnitzii</i> in intestinal epithelial cells through <i>Dact3</i> . <i>Gut Microbes</i> , 2020, 12, 1826748.	4.3	90
20	Identification of sulfur components enhancing the anti-Candida effect of <i>Lactobacillus rhamnosus</i> Lcr35. <i>Scientific Reports</i> , 2020, 10, 17074.	1.6	9
21	Protective Effect of Glycomacropeptide on Food Allergy with Gastrointestinal Manifestations in a Rat Model through Down-Regulation of Type 2 Immune Response. <i>Nutrients</i> , 2020, 12, 2942.	1.7	12
22	Evaluation of the Probiotic Properties and the Capacity to Form Biofilms of Various <i>Lactobacillus</i> Strains. <i>Microorganisms</i> , 2020, 8, 1053.	1.6	21
23	Gut Microbiota Abrogates Anti-Î±-Gal IgA Response in Lungs and Protects against Experimental <i>Aspergillus</i> Infection in Poultry. <i>Vaccines</i> , 2020, 8, 285.	2.1	26
24	Targeting Melanoma Hypoxia with the Food-Grade Lactic Acid Bacterium <i>Lactococcus Lactis</i> . <i>Cancers</i> , 2020, 12, 438.	1.7	13
25	Probiotics as Anti-Giardia Defenders: Overview on Putative Control Mechanisms. , 2020, , 335-349.		1
26	Oral delivery of pancreatitis-associated protein by <i>Lactococcus lactis</i> displays protective effects in dinitrobenzenesulfonic acid-induced colitis model and is able to modulate the composition of the microbiota. <i>Environmental Microbiology</i> , 2019, 21, 4020-4031.	1.8	15
27	From Probiotics to Psychobiotics: Live Beneficial Bacteria Which Act on the Brain-Gut Axis. <i>Nutrients</i> , 2019, 11, 890.	1.7	99
28	The potential probiotic <i>Lactobacillus rhamnosus</i> CNCM I-3690 strain protects the intestinal barrier by stimulating both mucus production and cytoprotective response. <i>Scientific Reports</i> , 2019, 9, 5398.	1.6	98
29	Phosphatidylglycerols are induced by gut dysbiosis and inflammation, and favorably modulate adipose tissue remodeling in obesity. <i>FASEB Journal</i> , 2019, 33, 4741-4754.	0.2	27
30	A New Bifidobacteria Expression System (BEST) to Produce and Deliver Interleukin-10 in <i>Bifidobacterium bifidum</i> . <i>Frontiers in Microbiology</i> , 2018, 9, 3075.	1.5	23
31	M cell-targeting strategy enhances systemic and mucosal immune responses induced by oral administration of nuclease-producing <i>L. lactis</i> . <i>Applied Microbiology and Biotechnology</i> , 2018, 102, 10703-10711.	1.7	12
32	Live bacterial biotherapeutics in the clinic. <i>Nature Biotechnology</i> , 2018, 36, 816-818.	9.4	17
33	Use of Traditional and Genetically Modified Probiotics in Human Health: What Does the Future Hold?. , 2018, , 363-370.		0
34	Bile Salt Hydrolase Activities: A Novel Target to Screen Anti-Giardia <i>Lactobacilli</i> ?. <i>Frontiers in Microbiology</i> , 2018, 9, 89.	1.5	38
35	Searching for the Bacterial Effector: The Example of the Multi-Skilled Commensal Bacterium <i>Faecalibacterium prausnitzii</i> . <i>Frontiers in Microbiology</i> , 2018, 9, 346.	1.5	84
36	A Versatile New Model of Chemically Induced Chronic Colitis Using an Outbred Murine Strain. <i>Frontiers in Microbiology</i> , 2018, 9, 565.	1.5	30

#	ARTICLE	IF	CITATIONS
37	Increased gut permeability in cancer cachexia: mechanisms and clinical relevance. <i>Oncotarget</i> , 2018, 9, 18224-18238.	0.8	90
38	Anti-tumoral Effects of Recombinant <i>Lactococcus lactis</i> Strain Secreting IL-17A Cytokine. <i>Frontiers in Microbiology</i> , 2018, 9, 3355.	1.5	28
39	Elucidating the Immune-Related Mechanisms by Which Probiotic Strain <i>Lactobacillus casei</i> BL23 Displays Anti-tumoral Properties. <i>Frontiers in Microbiology</i> , 2018, 9, 3281.	1.5	34
40	Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. <i>Microbial Cell Factories</i> , 2017, 16, 79.	1.9	581
41	Anti-cancer effect of lactic acid bacteria expressing antioxidant enzymes or IL-10 in a colorectal cancer mouse model. <i>International Immunopharmacology</i> , 2017, 42, 122-129.	1.7	57
42	Use of Traditional and Genetically Modified Probiotics in Human Health: What Does the Future Hold?. <i>Microbiology Spectrum</i> , 2017, 5, .	1.2	4
43	Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy <i>Lactococcus lactis</i> NZ9000 in the prevention of intestinal mucositis. <i>Microbial Cell Factories</i> , 2017, 16, 27.	1.9	51
44	Probiotic Strain <i>Lactobacillus casei</i> BL23 Prevents Colitis-Associated Colorectal Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1553.	2.2	156
45	Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis. <i>Frontiers in Microbiology</i> , 2017, 8, 800.	1.5	69
46	Functional Characterization of Novel <i>Faecalibacterium prausnitzii</i> Strains Isolated from Healthy Volunteers: A Step Forward in the Use of <i>F. prausnitzii</i> as a Next-Generation Probiotic. <i>Frontiers in Microbiology</i> , 2017, 8, 1226.	1.5	320
47	New Insights into the Diversity of the Genus <i>Faecalibacterium</i> . <i>Frontiers in Microbiology</i> , 2017, 8, 1790.	1.5	71
48	Contribution of sortase SrtA2 to <i>Lactobacillus casei</i> BL23 inhibition of <i>Staphylococcus aureus</i> internalization into bovine mammary epithelial cells. <i>PLoS ONE</i> , 2017, 12, e0174060.	1.1	14
49	Bile-Salt-Hydrolases from the Probiotic Strain <i>Lactobacillus johnsonii</i> La1 Mediate Anti-giardial Activity <i>In Vitro</i> and <i>In Vivo</i> . <i>Frontiers in Microbiology</i> , 2017, 8, 2707.	1.5	48
50	Gnotobiotic Rodents: An <i>In Vivo</i> Model for the Study of Microbe-Microbe Interactions. <i>Frontiers in Microbiology</i> , 2016, 7, 409.	1.5	57
51	<i>Bifidobacterium animalis</i> ssp. <i>lactis</i> CNCM-I2494 Restores Gut Barrier Permeability in Chronically Low-Grade Inflamed Mice. <i>Frontiers in Microbiology</i> , 2016, 7, 608.	1.5	50
52	A large scale <i>in vitro</i> screening of <i>Streptococcus thermophilus</i> strains revealed strains with a high anti-inflammatory potential. <i>LWT - Food Science and Technology</i> , 2016, 70, 78-87.	2.5	30
53	A new <i>lactobacilli in vivo</i> expression system for the production and delivery of heterologous proteins at mucosal surfaces. <i>FEMS Microbiology Letters</i> , 2016, 363, fnw117.	0.7	28
54	Anti-nociceptive effect of <i>Faecalibacterium prausnitzii</i> in non-inflammatory IBS-like models. <i>Scientific Reports</i> , 2016, 6, 19399.	1.6	72

#	ARTICLE	IF	CITATIONS
55	Identification of an anti-inflammatory protein from <i>Faecalibacterium prausnitzii</i> , a commensal bacterium deficient in Crohn's disease. <i>Gut</i> , 2016, 65, 415-425.	6.1	585
56	Expression of fibronectin binding protein A (FnBPA) from <i>Staphylococcus aureus</i> at the cell surface of <i>Lactococcus lactis</i> improves its immunomodulatory properties when used as protein delivery vector. <i>Vaccine</i> , 2016, 34, 1312-1318.	1.7	24
57	Identification of novel anti-inflammatory probiotic strains isolated from pulque. <i>Applied Microbiology and Biotechnology</i> , 2016, 100, 385-396.	1.7	54
58	Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis. <i>Journal of Medical Microbiology</i> , 2016, 65, 1038-1046.	0.7	17
59	The secreted L-arabinose isomerase displays anti-hyperglycemic effects in mice. <i>Microbial Cell Factories</i> , 2015, 14, 204.	1.9	12
60	Protective effect of TSLP delivered at the gut mucosa level by recombinant lactic acid bacteria in DSS-induced colitis mouse model. <i>Microbial Cell Factories</i> , 2015, 14, 176.	1.9	19
61	Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-8.	0.7	55
62	Effect of iron on the probiotic properties of the vaginal isolate <i>Lactobacillus jensenii</i> CECT 4306. <i>Microbiology (United Kingdom)</i> , 2015, 161, 708-718.	0.7	15
63	Identification of Metabolic Signatures Linked to Anti-Inflammatory Effects of <i>Faecalibacterium prausnitzii</i> . <i>MBio</i> , 2015, 6, .	1.8	206
64	Intranasal administration with recombinant <i>Lactococcus lactis</i> expressing heme oxygenase-1 reduces hyperoxia-induced lung inflammation in rat pups. <i>Biotechnology Letters</i> , 2015, 37, 1203-1211.	1.1	5
65	<i>Faecalibacterium prausnitzii</i> prevents physiological damages in a chronic low-grade inflammation murine model. <i>BMC Microbiology</i> , 2015, 15, 67.	1.3	208
66	Serine protease inhibitors protect better than IL-10 and TGF- $\beta$ 2 anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci. <i>Microbial Cell Factories</i> , 2015, 14, 26.	1.9	103
67	<i>Lactobacillus rhamnosus</i> CNCM I-3690 and the commensal bacterium <i>Faecalibacterium prausnitzii</i> A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice. <i>Gut Microbes</i> , 2015, 6, 1-9.	4.3	143
68	Drying process strongly affects probiotics viability and functionalities. <i>Journal of Biotechnology</i> , 2015, 214, 17-26.	1.9	80
69	Milk Fermented with a 15-Lipoxygenase-1-Producing <i>Lactococcus Lactis</i> Alleviates Symptoms of colitis in a Murine Model. <i>Current Pharmaceutical Biotechnology</i> , 2015, 16, 424-429.	0.9	28
70	The Indigenous Microbiota and its Potential to Exhibit Probiotic Properties. , 2015, , 181-194.		0
71	Effects in the use of a genetically engineered strain of <i>Lactococcus lactis</i> delivering in situ IL-10 as a therapy to treat low-grade colon inflammation. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1611-1621.	1.4	65
72	The role of metagenomics in understanding the human microbiome in health and disease. <i>Virulence</i> , 2014, 5, 413-423.	1.8	87

#	ARTICLE	IF	CITATIONS
73	Protective Effects of Lactococci Strains Delivering Either IL-10 Protein or cDNA in a TNBS-induced Chronic Colitis Model. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, S12-S17.	1.1	35
74	Genetically Engineered Immunomodulatory <i>Streptococcus thermophilus</i> Strains Producing Antioxidant Enzymes Exhibit Enhanced Anti-Inflammatory Activities. <i>Applied and Environmental Microbiology</i> , 2014, 80, 869-877.	1.4	85
75	The Commensal Bacterium <i>Faecalibacterium prausnitzii</i> Is Protective in DNBS-induced Chronic Moderate and Severe Colitis Models. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 417-430.	0.9	204
76	The Dual Role of MAPK Pathway in the Regulation of Intestinal Barrier. <i>Inflammatory Bowel Diseases</i> , 2014, 20, E17-E18.	0.9	6
77	Ecology and metabolism of the beneficial intestinal commensal bacterium <i>Faecalibacterium prausnitzii</i> . <i>Gut Microbes</i> , 2014, 5, 146-151.	4.3	128
78	Tu1778 <i>Faecalibacterium prausnitzii</i> Prevents Irritable Bowel Syndrome-Like Symptoms in Both Murine Low Grade Chronic Inflammation and Acute Stress Models. <i>Gastroenterology</i> , 2014, 146, S-840-S-841.	0.6	0
79	Tu1746 <i>Faecalibacterium prausnitzii</i> Provides Host Beneficial Metabolic Profile During Inflammation. <i>Gastroenterology</i> , 2014, 146, S-832.	0.6	0
80	Novel Role of the Serine Protease Inhibitor Elafin in Gluten-Related Disorders. <i>American Journal of Gastroenterology</i> , 2014, 109, 748-756.	0.2	56
81	83 Identification of an Anti-Inflammatory Protein From <i>Faecalibacterium prausnitzii</i> , a Deficient Commensal Bacteria Implicated in Crohn's Disease. <i>Gastroenterology</i> , 2014, 146, S-23.	0.6	0
82	Gut ecosystem: how microbes help us. <i>Beneficial Microbes</i> , 2014, 5, 219-233.	1.0	32
83	<i>Nuclease A</i> ( <i>Gbs</i> 0661), an extracellular nuclease of <i>S</i> <i>treptococcus agalactiae</i> , attacks the neutrophil extracellular traps and is needed for full virulence. <i>Molecular Microbiology</i> , 2013, 89, 518-531.	1.2	89
84	Engineering lactococci and lactobacilli for human health. <i>Current Opinion in Microbiology</i> , 2013, 16, 278-283.	2.3	148
85	Role of commensal and probiotic bacteria in human health: a focus on inflammatory bowel disease. <i>Microbial Cell Factories</i> , 2013, 12, 71.	1.9	188
86	Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface. <i>Applied Microbiology and Biotechnology</i> , 2013, 97, 1231-1239.	1.7	50
87	Tu1988 Impact of the Commensal Bacterium <i>Faecalibacterium prausnitzii</i> in a Non Active Inflammation Murine Model. <i>Gastroenterology</i> , 2013, 144, S-897-S-898.	0.6	1
88	<i>Faecalibacterium prausnitzii</i> and human intestinal health. <i>Current Opinion in Microbiology</i> , 2013, 16, 255-261.	2.3	829
89	Implications of the human microbiome in inflammatory bowel diseases. <i>FEMS Microbiology Letters</i> , 2013, 342, 10-17.	0.7	50
90	Identification of One Novel Candidate Probiotic <i>Lactobacillus plantarum</i> Strain Active against Influenza Virus Infection in Mice by a Large-Scale Screening. <i>Applied and Environmental Microbiology</i> , 2013, 79, 1491-1499.	1.4	92

#	ARTICLE	IF	CITATIONS
91	Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update. <i>FEMS Microbiology Letters</i> , 2013, 344, 1-9.	0.7	73
92	Development of a Stress-Inducible Controlled Expression (SICE) system in <i>Lactococcus lactis</i> for the production and delivery of therapeutic molecules at mucosal surfaces. <i>Journal of Biotechnology</i> , 2013, 168, 120-129.	1.9	93
93	Inactivation of the <i>ybdD</i> Gene in <i>Lactococcus lactis</i> Increases the Amounts of Exported Proteins. <i>Applied and Environmental Microbiology</i> , 2012, 78, 7148-7151.	1.4	4
94	Functional Analysis of the <i>Lactobacillus casei</i> BL23 Sortases. <i>Applied and Environmental Microbiology</i> , 2012, 78, 8684-8693.	1.4	55
95	Importance of Commensal and Probiotic Bacteria in Human Health. <i>Current Immunology Reviews</i> , 2012, 8, 248-253.	1.2	6
96	Mo1855 Oral Treatment With Elafin-Recombinant Probiotics Improves Visceral Pain and Hypersensitivity in a Model of Irritable Bowel Syndrome (IBS). <i>Gastroenterology</i> , 2012, 142, S-700-S-701.	0.6	0
97	Sa2060 Gnotobiotic Mice, a Promising Tool to Better Understand the Anti-Inflammatory Effects of <i>Faecalibacterium prausnitzii</i> ?. <i>Gastroenterology</i> , 2012, 142, S-392.	0.6	1
98	Mo2015 Food-Grade Lactic Acid Bacteria Expressing Elastase Inhibitors Protect From Intestinal Inflammation in Acute and Chronic Models of Colitis in Mice. <i>Gastroenterology</i> , 2012, 142, S-720.	0.6	0
99	Food-Grade Bacteria Expressing Elafin Protect Against Inflammation and Restore Colon Homeostasis. <i>Science Translational Medicine</i> , 2012, 4, 158ra144.	5.8	198
100	Sa2061 Protective and Curative Effect of <i>Faecalibacterium prausnitzii</i> in a Chronic DNBS-Induced Murine Colitis. <i>Gastroenterology</i> , 2012, 142, S-392.	0.6	3
101	Tu1842 Elastolytic Balance in IBD: the Elastase Inhibitor Elafin Prevents Loss of Barrier Function and Cytokines Release by Human Intestinal Epithelial Cells in IBD Conditions. <i>Gastroenterology</i> , 2012, 142, S-859.	0.6	0
102	Anti-inflammatory properties of dairy lactobacilli. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 657-666.	0.9	68
103	Mucosal co-immunization of mice with recombinant lactococci secreting VapA antigen and leptin elicits a protective immune response against <i>Rhodococcus equi</i> infection. <i>Vaccine</i> , 2011, 30, 95-102.	1.7	23
104	Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. <i>Microbial Cell Factories</i> , 2011, 10, S4.	1.9	180
105	Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. <i>EMBO Molecular Medicine</i> , 2011, 3, 559-572.	3.3	694
106	Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice. <i>Journal of Biotechnology</i> , 2011, 151, 287-293.	1.9	141
107	Intragastric administration of a superoxide dismutase-producing recombinant <i>Lactobacillus casei</i> BL23 strain attenuates DSS colitis in mice. <i>International Journal of Food Microbiology</i> , 2010, 144, 35-41.	2.1	117
108	Variations of N-acetylation level of peptidoglycan do not influence persistence of <i>Lactococcus lactis</i> in the gastrointestinal tract. <i>International Journal of Food Microbiology</i> , 2010, 144, 29-34.	2.1	6



#	ARTICLE	IF	CITATIONS
109	Perspectives for the development of human papillomavirus vaccines and immunotherapy. Expert Review of Vaccines, 2010, 9, 35-44.	2.0	15
110	Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium. BMC Research Notes, 2009, 2, 167.	0.6	19
111	Protective Effects of a Heme Oxygenase-1-Secreting <i>Lactococcus lactis</i> on Mucosal Injury Induced by Hemorrhagic Shock in Rats. Journal of Surgical Research, 2009, 153, 39-45.	0.8	14
112	Allergy Therapy by Intranasal Administration with Recombinant <i>Lactococcus lactis</i> Producing Bovine $\beta$ -Lactoglobulin. International Archives of Allergy and Immunology, 2009, 150, 25-31.	0.9	29
113	<i>Lactococcus lactis</i> as a live vector for mucosal delivery of therapeutic proteins. Hum Vaccin, 2009, 5, 264-267.	2.4	81
114	Development of Mucosal Vaccines Based on Lactic Acid Bacteria. , 2009, , 1099-1122.		2
115	Production of biological active murine IFN- $\gamma$ by recombinant <i>Lactococcus lactis</i> . FEMS Microbiology Letters, 2008, 280, 144-149.	0.7	27
116	Intragastric administration with recombinant <i>Lactococcus lactis</i> producing heme oxygenase-1 prevents lipopolysaccharide-induced endotoxemia in rats. FEMS Microbiology Letters, 2008, 283, 62-68.	0.7	10
117	Production of biologically active CXC chemokines by <i>Lactococcus lactis</i> : Evaluation of its potential as a novel mucosal vaccine adjuvant. Vaccine, 2008, 26, 5778-5783.	1.7	16
118	<i>Lactococcus lactis</i> ; an Efficient Cell Factory for Recombinant Protein Production and Secretion. Journal of Molecular Microbiology and Biotechnology, 2008, 14, 48-58.	1.0	214
119	<i>Faecalibacterium prausnitzii</i> is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16731-16736.	3.3	3,581
120	Current Prophylactic and Therapeutic Uses of a Recombinant <i>Lactococcus lactis</i> Strain Secreting Biologically Active Interleukin-12. Journal of Molecular Microbiology and Biotechnology, 2008, 14, 80-89.	1.0	11
121	Anti-inflammatory Properties of Lactic Acid Bacteria: Current Knowledge, Applications and Prospects. Anti-Infective Agents in Medicinal Chemistry, 2008, 7, 148-154.	0.6	10
122	Effects of Intranasal Administration of a Leptin-Secreting <i>Lactococcus lactis</i> Recombinant on Food Intake, Body Weight, and Immune Response of Mice. Applied and Environmental Microbiology, 2007, 73, 5300-5307.	1.4	33
123	Intranasal Coadministration of Live Lactococci Producing Interleukin-12 and a Major Cow's Milk Allergen Inhibits Allergic Reaction in Mice. Vaccine Journal, 2007, 14, 226-233.	3.2	43
124	Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. Vaccine, 2007, 25, 6581-6588.	1.7	79
125	Antimicrobial Activity of Divercin RV41 Produced and Secreted by <i>Lactococcus lactis</i> . Journal of Molecular Microbiology and Biotechnology, 2007, 13, 259-263.	1.0	5
126	Anti-inflammatory effects of <i>Lactobacillus casei</i> BL23 producing or not a manganese-dependant catalase on DSS-induced colitis in mice. Microbial Cell Factories, 2007, 6, 22.	1.9	109



#	ARTICLE	IF	CITATIONS
127	Consumption of Camembert cheese stimulates commensal enterococci in healthy human intestinal microbiota. <i>FEMS Microbiology Letters</i> , 2007, 276, 189-192.	0.7	14
128	Heterologous expression of <i>Brucella abortus</i> GroEL heat-shock protein in <i>Lactococcus lactis</i> . <i>Microbial Cell Factories</i> , 2006, 5, 14.	1.9	26
129	Immunomodulatory effects of IL-12 secreted by <i>Lactococcus lactis</i> on Th1/Th2 balance in ovalbumin (OVA)-induced asthma model mice. <i>International Immunopharmacology</i> , 2006, 6, 610-615.	1.7	38
130	Construction and characterization of a <i>Lactococcus lactis</i> strain deficient in intracellular ClpP and extracellular HtrA proteases. <i>Microbiology (United Kingdom)</i> , 2006, 152, 2611-2618.	0.7	44
131	Improvement of bovine $\gamma$ -lactoglobulin production and secretion by <i>Lactococcus lactis</i> . <i>Brazilian Journal of Medical and Biological Research</i> , 2005, 38, 353-359.	0.7	16
132	A Novel Mucosal Vaccine Based on Live Lactococci Expressing E7 Antigen and IL-12 Induces Systemic and Mucosal Immune Responses and Protects Mice against Human Papillomavirus Type 16-Induced Tumors. <i>Journal of Immunology</i> , 2005, 175, 7297-7302.	0.4	183
133	Protein secretion in <i>Lactococcus lactis</i> : an efficient way to increase the overall heterologous protein production. <i>Microbial Cell Factories</i> , 2005, 4, 2.	1.9	178
134	Cell-surface display of E7 antigen from human papillomavirus type-16 in <i>Lactococcus lactis</i> and in <i>Lactobacillus plantarum</i> using a new cell-wall anchor from lactobacilli. <i>Journal of Drug Targeting</i> , 2005, 13, 89-98.	2.1	78
135	An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci. <i>Journal of Medical Microbiology</i> , 2004, 53, 427-433.	0.7	135
136	Controlled intra- or extracellular production of staphylococcal nuclease and ovine omega interferon in <i>Lactococcus lactis</i> . <i>FEMS Microbiology Letters</i> , 2003, 224, 307-313.	0.7	73
137	Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein. <i>FEMS Microbiology Letters</i> , 2003, 229, 37-42.	0.7	74
138	Fusion to a Carrier Protein and a Synthetic Propeptide Enhances E7 HPV-16 Production and Secretion in <i>Lactococcus lactis</i> . <i>Biotechnology Progress</i> , 2003, 19, 1101-1104.	1.3	35
139	Intranasal Immunization with Recombinant <i>Lactococcus lactis</i> Secreting Murine Interleukin-12 Enhances Antigen-Specific Th1 Cytokine Production. <i>Infection and Immunity</i> , 2003, 71, 1887-1896.	1.0	119
140	Controlled Production of Stable Heterologous Proteins in <i>Lactococcus lactis</i> . <i>Applied and Environmental Microbiology</i> , 2002, 68, 3141-3146.	1.4	89
141	Production of Human Papillomavirus Type 16 E7 Protein in <i>Lactococcus lactis</i> . <i>Applied and Environmental Microbiology</i> , 2002, 68, 917-922.	1.4	116
142	Molecular sexing of monomorphic endangered Arab birds. <i>The Journal of Experimental Zoology</i> , 2002, 292, 677-680.	1.4	22
143	Loss of Restriction Site Ddel, used for Avian Molecular Sexing, in <i>Oreophasis derbianus</i> . <i>Reproduction in Domestic Animals</i> , 2002, 37, 321-323.	0.6	11